Provided by Tiger Fintech (Singapore) Pte. Ltd.

Syndax Pharmaceuticals

13.00
+0.08000.62%
Post-market: 13.000.00000.00%16:20 EDT
Volume:1.34M
Turnover:17.50M
Market Cap:1.12B
PE:-3.49
High:13.59
Open:13.35
Low:12.81
Close:12.92
Loading ...

Company Profile

Company Name:
Syndax Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
2005
Employees:
270
Office Location:
730 Third Avenue,9th Floor,New York,New York,United States
Zip Code:
10017
Fax:
- -
Introduction:
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
Briggs W. Morrison
Chief Executive Officer, Director
Dennis G. Podlesak
Chairman
Michael A. Metzger
President, Chief Operating Officer and Director
Fabrice Egros
Director
Jennifer Jarrett
Director
Keith A. Katkin
Director
Pierre Legault
Director
William Meury
Director

Shareholders

Name
Position
Briggs W. Morrison
Chief Executive Officer, Director
Michael A. Metzger
President, Chief Operating Officer and Director
Daphne Karydas
Chief Financial Officer
Luke J. Albrecht
Senior Vice President, General Counsel and Secretary
Michael L. Meyers
Senior Vice President, Chief Medical Officer
Peter Ordentlich
Chief Scientific Officer